
Zydus Lifesciences Limited has received FDA approval for ZITUVIMETTM, a medication containing sitagliptin and metformin hydrochloride to manage type 2 diabetes, available in two formulations, 50 mg/500 mg and 50 mg/1000 mg. The drug, an adjunct to diet and exercise, helps improve glycemic control in adults. ZITUVIMETTM's approval, based on extensive research and quality testing, expands Zydus' diabetes treatment offerings, enhancing healthcare accessibility and affordability. Dr. Sharvil Patel, Managing Director, emphasizes the medication's role in curbing drug spending growth and bolstering healthcare programs' financial sustainability. As per IQVIA™ data (MAT Aug-2023), the U.S. market for DPP-IV inhibitors and combinations is US$ 10 billion.
Like
Save
Share